Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease pyoderma gangrenosum
Comorbidity C0021831|bowel disease
Sentences 12
PubMedID- 23927379 Background and aim: to identify predictive factors related to the development of erythema nodosum and pyoderma gangrenosum, in patients with inflammatory bowel disease (ibd).
PubMedID- 23828140 Conclusions: oral corticosteroid therapy remains the most common treatment for pyoderma gangrenosum associated with inflammatory bowel disease.
PubMedID- 21532836 Cd2bp1 (pstpip1) and card15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease (table 1) [29].
PubMedID- 22104047 pyoderma gangrenosum associated with inflammatory bowel disease.
PubMedID- 25277124 pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study.
PubMedID- 21953808 Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease.
PubMedID- 25775631 pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study.
PubMedID- 20466360 [utility of infliximab in gangrenous pyoderma not associated with inflammatory bowel disease].
PubMedID- 21625613 Results: literature review of 10 cases confirmed the association of pyoderma gangrenosum with inflammatory bowel disease, hematological disease, and surgical trauma.
PubMedID- 21352279 Clinical implications of leukocytapheresis using a centrifugal cell separator for steroid-resistant pyoderma gangrenosum associated with inflammatory bowel disease.
PubMedID- 21958000 Successful treatment with infliximab for refractory pyoderma gangrenosum associated with inflammatory bowel disease.
PubMedID- 20645536 The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.

Page: 1